Arasappan, Dhivya
Eickhoff, Simon B.
Nemeroff, Charles B.
Hofmann, Hans A.
Jabbi, Mbemba http://orcid.org/0000-0001-5263-5321
Funding for this research was provided by:
National Institute of Mental Health
National Science Foundation
Mulva Clinics for the Neurosciences
Article History
Received: 8 May 2020
Accepted: 30 October 2020
First Online: 7 January 2021
Compliance with Ethical Standards
: The NIMH Human Brain Collection Core (HBCC) provided the Postmortem samples for which informed consent was acquired according to NIH institutional ethical review board (IRB) guidelines and clinical characterization, neuropathology screening, and toxicology analyses followed previous protocols [CitationRef removed]. In addition, the study received a human subject exemption from the University of Texas at Austin IRB given the anonymized nature of postmortem donor sample data that the research team received from the NIH.
: Dhivya Arasappan, none; Simon Eickhoff none; Hans Hofmann, none; Mbemba Jabbi, none.Charles B Nemeroff:Research/Grants: National Institutes of Health (NIH)Consulting (last year): Taisho Pharmaceutical, Inc., Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, Aditum BioStockholder: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA WellnessScientific Advisory Boards: Brain and Behavior Research Foundation (BBRF), Anxiety Disorders Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNSBoard of Directors: Gratitude America, ADAA, Xhale Smart, Inc.Income sources or equity of $10,000 or more: American Psychiatric Publishing, Xhale, Signant Health, CME Outfitters, Takeda, Intra-Cellular Therapies, Inc., EMA WellnessPatents: Method and devices for transdermal delivery of lithium (US 6,375,990B1)Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)Speakers Bureau: None